PT - JOURNAL ARTICLE AU - Simon de Lusignan AU - Mark Joy AU - Julian Sherlock AU - Manasa Tripathy AU - Oliver van Hecke AU - Oghenekome Gbinigie AU - John Williams AU - Christopher Butler AU - FD Richard Hobbs TI - PRINCIPLE trial demonstrates scope for in-pandemic improvement in primary care antibiotic stewardship AID - 10.1101/2021.02.02.21250902 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.02.21250902 4099 - http://medrxiv.org/content/early/2021/02/04/2021.02.02.21250902.short 4100 - http://medrxiv.org/content/early/2021/02/04/2021.02.02.21250902.full AB - Background The Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE) trial has provided in-pandemic evidence of what does not work in the early primary care management of coronavirus-2019 disease (COVID-19). PRINCIPLE’s first finding was that azithromycin and doxycycline were not effective.Aim To explore the extent to which azithromycin and doxycycline were being used in-pandemic, and the scope for trial findings impacting on practice.Design and Setting We compared crude rates of prescribing and respiratory tract infections (RTI) in 2020, the pandemic year, with 2019, using the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC).Methods We used a negative binomial model including age-band, gender, socioeconomic status, and NHS region to compare azithromycin and doxycycline lower respiratory tract infections (LRTI), upper respiratory tract infections (URTI), and influenza-like-illness (ILI) in 2020 with 2019; reporting incident rate ratios (IRR) between years and 95% confidence intervals (95%CI).Results Azithromycin prescriptions increased 7% in 2020 compared to 2019, whereas doxycycline decreased by 7%. Concurrently, LRTI and URTI incidence fell by over half (58.3% and 54.4% respectively) while ILI rose slightly (6.4%). The overall percentage of RTI prescribed azithromycin rose by 42.1% between 2019 and 2020, doxycycline increased by 33%.Our adjusted IRR showed azithromycin prescribing was 22% higher in 2020 (IRR=1.22, 95%CI:1.19-1.26, p<0.0001), for every unit rise in confirmed COVID there was an associated 3% rise in prescription (IRR=1.026, 95%CI 1.024-1.0285, p<0.0001); whereas these measures were static for doxycycline.Conclusion PRINCIPLE trial flags scope for improvement in antimicrobial stewardship.Competing Interest StatementChristopher Butler (CB) and FD Richard Hobbs (FDRH) are co-Principal and Simon de Lusignan (SdeL) an investigator of the PRINCIPLE trial. SdeL is Director of the Oxford-RCGP RSC.Clinical TrialISRCTN86534580Clinical Protocols https://publichealth.jmir.org/2020/3/e19773/ Funding StatementPRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research. FD Richard Hobbs acknowledges part support from the NIHR School for Primary Care Research (SPCR), the NIHR Applied Research Collaboration (ARC) Oxford, and the NIHR Oxford BRC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This investigation used pseudonymised data held by the Oxford-RCGP RSC sentinel network. The investigation is classified by the Health Research Authority Decision tool (http://www.hra-decisiontools.org.uk/research/) as not being considered research, and not requiring formal research ethics approval. This investigation was approved by the Oxford-RCGP RSC Joint Research and Surveillance Centre Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RCGP RSC dataset can be accessed by researchers, approval is on a project-by-project basis (www.rcgp.org.uk/rsc). Ethical approval by an NHS Research Ethics Committee is needed before any data release/other appropriate approval. Researchers wishing to directly analyse patient-level pseudonymised data will be required to complete information governance training and work on the data from the secure servers at the University of Oxford. Patient-level data cannot be taken out of the secure network.